Zhonghua Zhong Liu Za Zhi. 2025 Jun 23;47(6):443-455. doi: 10.3760/cma.j.cn112152-20250111-00021.
Lorlatinib is a novel third-generation anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitor (TKI) used for the treatment of patients with ALK-positive non-small cell lung cancer (NSCLC) patients. This drug exhibits high affinity, effectively overcoming various resistance mutations, and can penetrate the blood-brain barrier, demonstrating significant efficacy against brain metastases. Lorlatinib exhibits generally manageable safety profiles. To improve patients' adherence and maximize patients survival outcome, physicians need pay attention to lorlatinib related adverse events such as hyperlipidemia, edema, and hypertension, necessitating dose adjustments and symptom management based on individual patient conditions. The Beijing Cancer Prevention and Treatment Research Association has organized relevant experts to formulate the "Lorlatinib primary hospital patient health management expert consensus (2025 edition)". This expert consensus provides standardized guidance on the use of lorlatinib for primary hospitals, including pharmacological characteristics, indications, dosage, high-level evidence-based medical research, adverse event management strategy and individualized treatment options. The consensus emphasizes the periodically monitor, identification, assessment, and management of adverse reactions, as well as the importance of long-term follow-up, aiming to maximize the clinical benefits of lorlatinib, ensure the therapeutic effectiveness, improve patients' quality of life and achieve long-term survival.
洛拉替尼是一种新型的第三代间变性淋巴瘤激酶（ALK）酪氨酸激酶抑制剂（TKI），用于治疗ALK阳性非小细胞肺癌（NSCLC）患者。该药物具有高亲和力，能有效克服各种耐药突变，且可穿透血脑屏障，对脑转移瘤显示出显著疗效。洛拉替尼的安全性总体上易于管理。为提高患者依从性并最大化患者生存结局，医生需要关注洛拉替尼相关的不良事件，如高脂血症、水肿和高血压，这需要根据患者个体情况进行剂量调整和症状管理。北京癌症防治研究协会组织相关专家制定了《洛拉替尼基层医院患者健康管理专家共识（2025年版）》。该专家共识为基层医院使用洛拉替尼提供了标准化指导，包括药理特性、适应证、剂量、高级别循证医学研究、不良事件管理策略和个体化治疗方案。共识强调对不良反应进行定期监测、识别、评估和管理，以及长期随访的重要性，旨在最大化洛拉替尼的临床获益，确保治疗效果，改善患者生活质量并实现长期生存。
